top of page

How AI Is Transforming Clinical Development Drug Discovery Recruitment and Trial Management

sharonshieldsconsu
Oct 23
9 min read

Clinical development has always carried a painful contradiction. Science can point to promising biology, yet turning that promise into a tested therapy can take years of trial design, patient matching, site coordination and regulatory work. Many compounds fail late. Many trials struggle to enrol. Many teams spend too much time searching for patterns that sit hidden in papers, scans, genomic files and electronic health records.


AI is changing that rhythm.


It is not replacing scientists, clinicians or trial teams. The real advance is more practical. AI can scan huge bodies of data, spot signals earlier, suggest better experiments and help teams run studies with fewer blind spots. The result is a field that is becoming faster, more targeted and more adaptive.


This article is informational only and does not provide medical advice.


Wide-angle view of a laboratory bench with protein models and sample trays.
AI is helping researchers connect biological clues faster than before.

AI is changing the earliest choices in drug discovery


The first stage of clinical development starts before a trial protocol exists. Researchers need to choose which disease biology to target, which molecules to test and which compounds have a realistic chance of becoming safe medicines.


AI helps at each step by finding relationships across data that would be hard to see by manual review.


A drug discovery team may work with:


  • Genomic and proteomic datasets

  • Scientific literature

  • Chemical libraries

  • Protein structures

  • Disease registries

  • Safety databases

  • Imaging data

  • Real-world clinical records


Traditional methods use these sources too, but AI can compare them at speed and scale. Machine learning models can suggest which targets matter most in a disease pathway. Generative models can propose new molecules. Prediction systems can flag possible toxicity, poor absorption or manufacturing challenges earlier.


That matters because every weak candidate removed before a trial saves time, money and patient burden.


AlphaFold made protein structure prediction practical at scale


One of the clearest examples is AlphaFold, developed by DeepMind. Protein structure has long been central to understanding disease and designing medicines. The shape of a protein affects how it behaves and how a drug might bind to it.


For decades, scientists used methods such as X-ray crystallography and cryo-electron microscopy to solve structures. These methods remain vital, but they can be slow and technically demanding. AlphaFold changed expectations by predicting protein structures with a level of accuracy that made the wider research community take notice.


The release of a large public database of predicted protein structures gave researchers access to models for more than 200 million proteins. This did not make laboratory validation unnecessary, but it gave scientists a much stronger starting point.


For clinical development, the effect is indirect but powerful. Better structural insight can support:


  • More informed target selection

  • Faster design of binding molecules

  • Better understanding of resistance mechanisms

  • Stronger hypotheses before animal or human testing


In drug discovery, better questions are often as valuable as better answers.


AI-designed molecules are now reaching human studies


Several companies have moved from AI-assisted research into clinical testing. Exscientia, working with Sumitomo Pharma, drew attention when an AI-designed drug candidate for obsessive-compulsive disorder entered human testing. The programme showed that AI could contribute not only to screening existing compounds, but also to designing new ones.


Insilico Medicine has also advanced AI-discovered drug candidates into clinical studies, including work in idiopathic pulmonary fibrosis. These examples do not prove that AI-designed drugs will always succeed. Most drug candidates, regardless of origin, still face a high risk of failure. They do show that AI can help produce candidates credible enough to test in people.


A more subtle breakthrough is the shift from searching to designing. Instead of asking, “Which molecule in this library looks useful?”, researchers can ask, “What molecule should exist for this target and disease context?”


That change opens new space for rare diseases, complex biology and targets that once looked too difficult.


AI is making drug repurposing faster


Drug discovery does not always mean inventing a new compound. Sometimes the fastest route is to discover a new use for an existing medicine.


AI can compare disease pathways, gene expression patterns, drug mechanisms and clinical data to suggest repurposing opportunities. During the COVID-19 pandemic, BenevolentAI identified baricitinib, a medicine already used in inflammatory disease, as a potential treatment because of its immune effects and possible relevance to viral infection pathways.


Baricitinib later went through clinical evaluation for COVID-19 and became part of treatment discussions in some settings. The key lesson is not that an algorithm “found a cure”. It did not. The lesson is that AI helped surface a plausible candidate quickly enough for scientists and clinicians to test it during an urgent public health crisis.


That is the right model for AI in clinical development. It proposes. Humans evaluate. Trials decide.


Patient recruitment is becoming more precise and less manual


Recruitment is one of the most stubborn problems in clinical trials. A protocol may look strong on paper, but a study fails if the right participants cannot be found, contacted, screened and retained.


The challenge is especially sharp in oncology, rare diseases and trials that use biomarkers. A patient may need a specific diagnosis, treatment history, lab result, genetic alteration and disease stage. That information often sits across pathology reports, clinician notes, scan reports and hospital systems.


AI can help by reading structured and unstructured data, then matching patients to trial criteria more accurately.


Natural language processing can find hidden eligibility clues


A major use case is natural language processing, often called NLP. This branch of AI can interpret text in clinical notes, discharge summaries and pathology reports.


For example, a trial may require that a patient has previously received two specific therapies, has no certain heart condition and carries a tumour mutation found in a molecular report. Human coordinators can search for this, but it takes time. AI tools can scan records and flag patients who appear eligible, then the clinical team confirms the match.


Companies such as Tempus, Flatiron Health, TriNetX and Deep 6 AI have worked in this area, using clinical and real-world data to support trial matching, site feasibility and cohort discovery. The goal is not to automate consent or bypass clinicians. The goal is to reduce missed opportunities.


For patients, this can mean learning about a relevant trial sooner. For sponsors and sites, it can mean fewer stalled studies and fewer protocol amendments caused by unrealistic enrolment assumptions.


AI can improve site selection before recruitment begins


Recruitment problems often start with poor site selection. A sponsor may choose sites based on past relationships or broad disease volume, only to learn later that few patients meet the exact criteria.


AI can combine historical enrolment data, disease prevalence, demographic information, lab testing patterns and real-world treatment data to predict which sites are likely to find eligible participants. This is especially useful when a trial needs patients with a narrow biomarker profile.


Better site selection can also support diversity. If teams examine where eligible patients actually receive care, not just where trials have traditionally been placed, they can make studies more accessible. AI cannot solve health inequality on its own, but it can reveal gaps that trial planners might otherwise miss.


Clinical trial management is becoming more adaptive


Once a trial starts, the work becomes operationally intense. Teams track enrolment, protocol deviations, safety events, data quality, site performance and participant retention. Large studies can produce a constant flow of information from electronic data capture systems, laboratories, imaging centres, wearables and patient-reported outcome tools.


AI helps by turning that flow into earlier warnings.


Eye-level view of a person using a wearable health sensor beside a glass of water.
Wearable sensors can feed trial teams with real-world health signals.

Risk-based monitoring is gaining sharper signals


Risk-based monitoring focuses attention on the sites, data points and processes most likely to affect patient safety or trial reliability. AI can support this approach by detecting unusual patterns, such as:


  • A site reporting data much faster or slower than similar sites

  • Unexpected changes in adverse event reporting

  • Repeated missing values in key fields

  • Outlier lab results that need review

  • Data patterns that suggest training issues


This does not remove the need for monitors or data managers. It gives them a better map of where to look first.


Platforms from companies such as Medidata and Saama have brought AI and analytics into trial operations, including enrolment forecasting, data review and study oversight. The most useful systems do not drown teams in alerts. They help separate routine noise from signals that could affect quality or safety.


Digital endpoints are creating new measures of health


AI also matters because trials are measuring health in new ways. Wearable devices, smartphone-based assessments and home monitoring tools can capture signals that a clinic visit might miss.


In neurological disease, movement patterns may reveal changes in tremor, gait or sleep. In respiratory disease, connected devices may track symptoms and activity. In heart disease, remote monitoring can help follow rhythm or exertion patterns.


AI can analyse these data streams and turn them into potential digital endpoints. That could make trials more sensitive to real changes in daily life. It could also reduce reliance on infrequent clinic snapshots.


Regulators still expect evidence that these measures are valid, reliable and meaningful. Digital endpoints need careful testing. Yet the direction is clear: clinical trials are moving closer to the patient’s real world.


AI is improving protocol design and feasibility


A clinical trial protocol is both a scientific plan and an operational blueprint. If it is too narrow, recruitment suffers. If endpoints are poorly chosen, the study may fail to answer the right question. If visit schedules are too demanding, participants may drop out.


AI can help teams test a protocol before it reaches sites.


By comparing proposed criteria with real-world data, teams can estimate how many patients may qualify. They can see which inclusion or exclusion rules remove the largest number of candidates. They can model how changes might affect feasibility without weakening the science.


This is especially valuable in precision medicine. A cancer trial may target a mutation found in only a small share of patients. AI can help identify where testing occurs, how often the mutation appears and which combinations of criteria make enrolment realistic.


The same applies to decentralised and hybrid trials. AI can help decide which visits require in-person assessment, which data can be collected remotely and where participant burden may be too high.


The gains are real, but the limits matter


AI in clinical development brings clear benefits, but it also raises hard questions.


The first is data quality. AI trained on incomplete, biased or inconsistent data can produce misleading results. A model may perform well in one hospital system and poorly in another. If underrepresented groups are missing from the data, the model may fail the very patients trial teams need to include.


The second is explainability. Scientists and regulators need to understand why a model recommends a target, flags a patient or predicts a trial risk. Black-box outputs can be hard to trust, especially when patient safety is involved.


The third is governance. Clinical development teams need clear rules for validation, audit trails, data privacy and human review. AI can support decisions, but accountability remains with the people and organisations using it.


A useful rule is simple: AI should make clinical development more evidence-led, not less transparent.


What the next generation of clinical development may look like


The next stage will likely combine several AI uses into a connected development process.


A future therapy programme may begin with AI-assisted target discovery, supported by protein structure prediction and disease modelling. Generative systems may propose molecules, while predictive models screen out weak candidates. Real-world data may shape the first protocol. Trial matching tools may help sites find eligible patients. During the study, AI may track risk, data quality and patient burden in near real time.


That does not mean trials become automatic. Clinical judgement, ethics review, patient consent, regulatory oversight and laboratory validation remain central. The best future is not a fully automated trial. It is a better-informed trial.


The most promising advances share a pattern. They reduce wasted effort. They bring hidden signals into view. They help teams learn earlier, before costs rise and patients wait.


AI has moved from a research curiosity to a practical tool across drug discovery, patient recruitment and trial management. Its biggest contribution may be cultural as well as technical: it pushes clinical development to become more precise, more responsive and more honest about what the data can and cannot show.


The takeaway is clear. AI will not remove the uncertainty of developing new medicines. It can help teams face that uncertainty sooner, with better evidence and better choices.



References

  1. U.S. Food and Drug Administration. Artificial Intelligence and Machine Learning (AI/ML) in Drug Development. FDA.

  2. Jumper J, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–589. doi:10.1038/s41586-021-03819-2.

  3. World Health Organization. Ethics and Governance of Artificial Intelligence for Health. WHO; 2021.

  4. U.S. Food and Drug Administration. Digital Health Technologies for Remote Data Acquisition in Clinical Investigations. FDA guidance.

  5. ClinicalTrials.gov. ClinicalTrials.gov: A database of privately and publicly funded clinical studies. U.S. National Library of Medicine.

  6. European Medicines Agency. Reflection paper on the use of artificial intelligence in the medicinal product lifecycle. EMA.


Disclaimer: AI can support research and clinical-development decisions, but it does not replace qualified medical, scientific, ethical, or regulatory expertise.


Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page